LB PHARMACEUTICALS INC (LBRX)
Health Care · Late-stage antipsychotic drug development · NASDAQ
Late-stage biotech bringing LB-102, a novel antipsychotic with potential across schizophrenia, bipolar depression, and major depressive disorder, to a $12B+ US branded antipsychotic market.
What LB PHARMACEUTICALS INC does
LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for neuropsychiatric disorders. The company's lead product, LB-102, is a new chemical entity and methylated derivative of amisulpride (a second-generation antipsychotic approved in over 50 countries) currently in pivotal Phase 3 clinical trials for schizophrenia and Phase 2 trials for bipolar depression and major depressive disorder. LB-102 is designed to address limitations of existing antipsychotics with a differentiated therapeutic profile and strong intellectual property protection.
Themes: ["antipsychotics / schizophrenia","bipolar disorder treatment","major depressive disorder","CNS / neuropsychiatric","Phase 3 clinical trials"]
Fundamentals
- Price$33.74 as of 2026-07-09 close
- Market cap$980M as of 2026-07-10
- 1-year return+53.5% as of 2026-07-09 close
- ROE-17.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.27 as of 2026-07-10
Key risks (from latest filing)
["Clinical and regulatory risk: LB-102 is a new chemical entity currently in Phase 3 trials; clinical development failure or adverse findings could prevent FDA approval or commercialization","Competition and market acceptance: Multiple branded and generic antipsychotics already dominate the ~$12B US market; physician and patient adoption of LB-102 remains uncertain","Funding and cash runway: Company's continued operations depend on securing adequate financing to complete clinical trials, regulatory submissions, and eventual commercialization"]
Competitors & peers
- Janssen Pharmaceuticals (risperidone/Risperdal)
- Eli Lilly (olanzapine/Zyprexa)
- AstraZeneca (quetiapine/Seroquel)
- Allergan (paliperidone/Invega)
- Otsuka (aripiprazole/Abilify)
- Intra-Cellular Therapies
- Perception Neuroscience
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.